Sign inJoin waitlistJoin the waitlist

Elena Shagisultanova

Clinical Faculty · University of Colorado School of Medicine

Credentials: · · · · · · · ·

History

University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present

Hematology and Medical Oncology
Fox Chase Cancer Center
2000–2003
Internal Medicine
UCSF Health Stanyan Hospital
1997–2000
Bashkir State Medical University
1993–1997

Research

Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases
Review · Gene · 2015 · First of 5 authors · 63 citations
PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Review · JCO Precision Oncology · 2022 · Last of 6 authors · Corresponding · 59 citations
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Molecular Cancer Therapeutics · 2016 · 44 citations

Virginia Borges
12 papers
Jennifer Diamond
8 papers
Peter Kabos
8 papers
Anthony Elias
5 papers
AA
Anosheh Afghahi
4 papers
JM
Jose Mayordomo
4 papers
Christine Fisher
3 papers
Gregory Vidal
2 papers
Jody Kagihara
2 papers · 2 as a fellow
Rachel Rabinovitch
2 papers
Sharon Sams
2 papers
Wafik El-Deiry
2 papers

Grants

Discovering Mechanisms of Sensitivity and Resistance to Triple Combination Targeted Therapy in HR+/HER2+ Breast Cancer
National Cancer Institute · K08
Contact PI · $1.2M · University of Colorado Denver
2019–2024

Clinical trials

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Principal investigator · Active not recruiting · Phase 1, Phase 2
Criterium, Inc.
2022–2026
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Principal investigator · Completed · Phase 1, Phase 2
University of Colorado, Denver
2017–2023
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Site PI · Recruiting · Phase 2
Biostar Pharma, Inc.
2025–2027